Table 1. The patients baseline characteristics (Pearson chi2 and ANOVA test p-values of the differences between the groups).
| All cases n=301, (%) |
Primary CIS n=72 (23.9%) |
Secondary CIS n=58 (19.3%) |
Concomitants CIS n=171 (56.8%) |
P value | |
|---|---|---|---|---|---|
| Gender (M/F) | 246 (81.7)/55 (18.3) | 59 (81.9)/13 (18.1) | 48 (82.8)/10 (17.2) | 139 (81.3)/32 (18.7) | 0.968 |
| Age (mean; SD) | 67.2; 8.72 | 67.3; 9.0 | 69.2; 9.9 | 66.6; 8.1 | 0.141 |
| Observation time months (mean; SD) | 61.9; 50.1 | 65.3; 52.0 | 55.2; 30.5 | 62.8; 55.7 | 0.504 |
| Recurrence | 113 (37.5) | 27 (37.5) | 18 (31) | 68 (39.8) | 0.495 |
| Progression | 78 (25.9) | 25 (34.7) | 11 (19) | 42 (24.6) | 0.104 |
| Cancer specific death | 44 (14.6) | 13 (18.1) | 5 (8.6) | 26 (15.2) | 0.155 |
| Number of papillary tumours (solitary/multiple/unk) | 68 (39.8)/90 (52.6)/13 (7.6) | ||||
| Papillary tumour size (<3 cm/3 cm/unk) | 48 (28.1)/109 (63.7)/14 (8.2) | ||||
| Papillary tumour stage (Ta/T1) | 96 (56.1)/75 (43.9) | ||||
| Papillary tumour grade WHO1973 (1/2/3) | 25 (14,6)/80 (46.8)/66 (38.6) |
The value of adjusted P<0.05 was considered statistically significant. CIS, carcinoma in situ; M, male; F, female; SD, standard deviation; unk, unknown.